Top 5 Safest Stocks To Invest In 2023


One day many years ago, I found myself stuck in traffic and noticed a peculiar sign. It said something about the construction that was going on — the very thing that was hampering my commute.

It said all this construction was being funded by a bond. This was before I had ever started my career in finance, so bonds were an unfamiliar thing. But when I began my investment career, I soon realized that I could actually invest in these things. And the more I learned, the more I was ecstatic.

After all, If you can’t beat ’em, might as well make money off them…

You see, these types of bonds have a name — general obligation bonds — a type of municipal, or “muni” bond for short. These bonds are used for everything from helping fund road construction to building schools, bridges, water infrastructure and other public buildings. As I became more familiar with municipal bonds, I quickly became a fan. In fact, in my experience, muni-bonds are one of the safest ways for investors to earn income in today’s market — while also beating the tax man. (More on that in a moment.)

Top 5 Safest Stocks To Invest In 2023: NeuroMetrix Inc.(NURO)


NeuroMetrix, Inc., a science-based health care company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease, and spinal stenosis. The company focuses on diagnosis and treatment of the neurological complications of diabetes, including diabetic peripheral neuropathy (DPN) and median neuropathy. Its marketed products include the ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the diagnosis and evaluation of CTS, low back and leg pain, and DPN; and the NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as DPN at the point-of-care, as well as consumables and accessories for use with its neurodiagnostic equipment. The company is also developing SENSUS pain therapy device, a transcutaneous electrical nerve stimul ator used in the management of chronic pain, such as that caused by DPN; and ADVANCE CTS, a version of the ADVANCE NCS/EMG device for the detection of CTS in people with diabetes. The company distributes its products directly through its direct sales force and independent sales representatives to physicians, clinics, and hospitals consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology/podiatry market in the United States and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.


Advisors’ Opinion:

  • [By Shane Hupp]

    Haemonetics (NYSE: HAE) and Neurometrix (NASDAQ:NURO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Top 5 Safest Stocks To Invest In 2023: Delaware Enhanced Global Dividend(DEX)

Delaware Enhanced Global Dividend & Income Fund (the Fund), is a closed-end diversified management investment company with no operating history. The Fund’s primary investment objective is to seek current income, with a secondary objective of capital appreciation. The Fund invests at least 80% of its total assets in a combination of dividend-paying or income-generating securities across multiple asset classes, including but not limited to, equity securities of large, well-established companies; securities issued by real estate companies (including REITs and REOCs), debt securities (such as government bonds, investment grade and high-yield corporate bonds, and convertible bonds), and emerging market securities. The Fund may invest in a variety of income generating equity and debt securities.


The Fund may purchase securities in any foreign country, developed or emerging markets. The Fund anticipates investing in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Hong Kong, Ireland, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Portugal, Singapore, Spain, Sweden, Switzerland, Taiwan, and the United Kingdom.

Advisors’ Opinion:

  • [By Ethan Ryder]

    1607 Capital Partners LLC trimmed its position in shares of DE ENHANCED GLB/COM (NYSE:DEX) by 45.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,493 shares of the company’s stock after selling 49,984 shares during the period. 1607 Capital Partners LLC’s holdings in DE ENHANCED GLB/COM were worth $518,000 at the end of the most recent quarter.

  • [By Max Byerly]

    DEX (CURRENCY:DEX) traded 17.7% lower against the U.S. dollar during the 1-day period ending at 19:00 PM E.T. on February 16th. One DEX token can currently be purchased for $0.0382 or 0.00001051 BTC on popular cryptocurrency exchanges including IDAX and Coinbit. DEX has a market cap of $7.31 million and $2.95 million worth of DEX was traded on exchanges in the last day. Over the last week, DEX has traded 28.8% lower against the U.S. dollar.

Top 5 Safest Stocks To Invest In 2023: YPF Sociedad Anonima(YPF)


YPF is a corporation (sociedad anónima), incorporated under the laws of Argentina for a limited term. Our address is Macacha Güemes 515, C1106BKK Ciudad Autónoma de Buenos Aires, Argentina and our telephone number is (011-54-11) 5441-2000. Our legal name is YPF Sociedad Anónima and we conduct our business under the commercial name “YPF.”
We are Argentina’s leading energy company, operating a fully integrated oil and gas chain with leading market positions across the domestic upstream and downstream segments. Our upstream operations consist of the exploration, development and production of crude oil, natural gas and LPG. Our downstream operations include the refining, marketing, transportation and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG and bio-fuels. Additionally, we are active in the gas separation and natural gas distribution sectors both directly and through our investments in several affiliated companies.   Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on YPF (YPF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    YPF (NYSE:YPF) and HollyFrontier (NYSE:HFC) are both oils/energy companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on YPF (YPF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    YPF (NYSE:YPF) had its target price decreased by equities researchers at Bank of America from $26.00 to $22.00 in a report issued on Friday, Stock Target Advisor reports. The firm presently has a “buy” rating on the oil and gas exploration company’s stock. Bank of America’s price target would indicate a potential upside of 47.65% from the company’s current price.

Top 5 Safest Stocks To Invest In 2023: Cassava Sciences, Inc.(SAVA)


Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Advisors’ Opinion:

  • [By Louis Navellier and the InvestorPlace Research Staff]

    Since biotechnology company Cassava Sciences (NASDAQ:SAVA) is working hard to fight Alzheimer’s disease, it might be surprising to know that the company has some harsh critics. There’s a lot of drama going on with Cassava, and SAVA stock traders need to be aware of the latest developments.

  • [By Larry Ramer]

    Allegations of fraud against Cassava Sciences (NASDAQ:SAVA) are unlikely to stop its Alzheimer’s drug candidate from quickly advancing to a Phase 3 clinical trial. As a result, I remain very bullish on SAVA stock.

  • [By ]

    Cassava Sciences  (SAVA) – Get Cassava Sciences, Inc. Report tumbled Friday after the drugmaker's CEO issued a statement rebutting recent allegations against the quality of testing for the company's Alzheimer's disease treatment and was attacked on social media.

Top 5 Safest Stocks To Invest In 2023: Syndax Pharmaceuticals, Inc. (SNDX)

We are a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer, or TNBC. Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients.   Advisors’ Opinion:

  • [By Logan Wallace]

    A number of brokerages have recently issued reports on SNDX. B. Riley began coverage on shares of Syndax Pharmaceuticals in a research report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 price target on the stock. ValuEngine downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $16.25.

    COPYRIGHT VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Thursday” was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at www.tickerreport.com/banking-finance/4188416/syndax-pharmaceuticals-sndx-set-to-announce-earnings-on-thursday.html.

    About Syndax Pharmaceuticals

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published.